@article{c91d2bb39d584c0daeb83b39b8912278,
title = "More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L",
abstract = "The present post hoc analysis of two 30-week clinical trials compared efficacy and hypoglycaemia outcomes at early study visits with iGlarLixi (insulin glargine U100 [iGlar] and lixisenatide) vs iGlar alone in patients with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs; LixiLan-O trial) or basal insulin (LixiLan-L trial). Time to control, defined as days to achieve glycated haemoglobin (HbA1c) <53 mmol/mol (<7%) or fasting plasma glucose (FPG) ≤7.2 mmol/L, was estimated using the Kaplan–Meier method. In the LixiLan-O and LixiLan-L trials, 60% and 46% of patients, respectively, reached HbA1c <53 mmol/mol (<7%) with iGlarLixi at 12 weeks, vs 45% and 24%, respectively, with iGlar. In the LixiLan-O trial, the median time to target HbA1c was approximately half with iGlarLixi vs iGlar (85.0 vs 166.0 days; P <.0001). In the LixiLan-L trial, the median time to target HbA1c was 153.0 days with iGlarLixi, while target HbA1c was never reached by 50% of patients with iGlar (P <.0001). Time-to-target FPG and hypoglycaemia outcomes were similar between treatments. In T2D uncontrolled on OADs or basal insulin, iGlarLixi resulted in glycaemic control in more patients than did iGlar at early treatment time points.",
keywords = "GLP-1, glycaemic control, insulin therapy, type 2 diabetes",
author = "Juan Frias and {Puig Domingo}, Manuel and Luigi Meneghini and Raffaele Napoli and Minzhi Liu and {Soltes Rak}, Erika and Aroda, {Vanita R.}",
note = "Funding Information: information This post hoc analysis was funded by Sanofi.The LixiLan-O and LixiLan-L trials were sponsored by Sanofi. Editorial assistance was provided by Kate Jesien of Caudex, New York, and Jane Bryant of Caudex, Oxford, funded by Sanofi. Previously presented at the 77th Scientific Sessions of the American Diabetes Association, June 9 to 13, 2017, San Diego, CA, USA, 1084-P and the 53rd Annual Meeting of the European Association for the Study of Diabetes, September 11 to 15, 2017, Lisbon, Portugal, 803. J.F. has received research support from AbbVie, Allergan, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Elcelyx, Eli Lilly, Genentech, IONIS, Janssen, Johnson and Johnson, Lexicon, Ligand, Madrigal, Merck, Mylan, Myovant, Novartis, Novo Nordisk, Ogeda, Pfizer, Sanofi, TaiwanJ, Theracos and Viking, and has received advisory board and consulting fees from AstraZeneca, Bristol-Myers Squibb, Echosens, Elcelyx, Johnson and Johnson, Ligand, Novo Nordisk and Sanofi. M.P.D. has received advisory board fees from Eli Lilly, Intarcia Therapeutics, Novo Nordisk and Sanofi, has received research support from MSD and speakers' bureau fees from Eli Lilly, Novo Nordisk and Sanofi. L.M. has received advisory panel and consulting fees from Novo Nordisk and Sanofi. R.N. has received consulting fees from Eli Lilly, MSD and Sanofi, and research support from Rottapharm, is an employee of Federico II University, Naples, Italy and has received speakers' bureau fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, MSD, Sanofi and Sigma Tau. M.L. has received consulting fees from BDM Consulting, Inc. and Sanofi. E.S.R. is an employee of Belcan. V.R.A. has received consulting fees from Adocia, AstraZeneca, Janssen, Novo Nordisk and Sanofi, is an employee of MedStar Health Research Institute and has received research support from Amylin, AstraZeneca, Bristol-Myers Squibb, Eisai, Janssen, Novo Nordisk, Sanofi and Theracos. J.F., M.P.D., L.M., R.N. and V.R.A. contributed data analysis/interpretation and critical revision of the manuscript for important intellectual content. M.L. contributed data acquisition, analysis and interpretation, and critical revision of the manuscript for important intellectual content. E.S.R. contributed study conception and design, data analysis/interpretation and critical revision of the manuscript for important intellectual content. All authors confirm that they meet the International Committee of Medical Journal Editors uniform requirements for authorship and that all authors have read, reviewed and agreed to the final version. Publisher Copyright: {\textcopyright} 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.",
year = "2018",
month = sep,
doi = "10.1111/dom.13368",
language = "English (US)",
volume = "20",
pages = "2314--2318",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "9",
}